EXPLORINEER
en

Archive — US — turtlesai

OpenAI and FDA Explore Using AI to Streamline Drug Evaluation

OpenAI and the FDA are collaborating to integrate AI into drug evaluation processes. The 'cderGPT' project aims to enhance the efficiency and accuracy of regulatory reviews. While the FDA has taken initial steps with its first AI-assisted review, challenges regarding data quality and AI model reliability persist, prompting the establishment of frameworks and councils to ensure safe implementation.

Key points

  • OpenAI and FDA are in talks to use AI for drug evaluation, aiming to improve efficiency.
  • The 'cderGPT' project will assist the FDA's Center for Drug Evaluation and Research (CDER).
  • The FDA has conducted its first AI-assisted scientific review.
  • Concerns about AI model reliability and data quality have been highlighted by experts.
  • The FDA released interim guidance proposing a risk-based approach to AI model assessment.
  • The CDER AI Council was established to support AI-related initiatives and ensure responsible use.

Why it matters

  • This partnership aligns with the growing trend in 2025 towards AI integration in various regulatory frameworks.
  • Historically, FDA has been cautious in adopting new technologies, reflecting a balance between innovation and safety.
  • The establishment of AI councils and guidelines by regulatory bodies indicates a broader acceptance of AI in healthcare sectors.

The collaboration between OpenAI and the FDA represents a pivotal moment in drug evaluation, seeking to balance innovation with safety and reliability through effective AI integration.